About this trial
Summary Points:
1. High Risk Breast Cancers: Triple negative cancer is considered high risk due to high rate of local and systemic failure. Newer innovative treatment strategies are needed to improve systemic control of disease and survival. 2. Immune system modulation: is an emerging modality in cancer treatment. Tumor antigens can stimulate T cells to identify and destroy cancer cells. Cancers express "altered self" antigens that tend to induce weaker responses than the "foreign" antigens expressed by infectious agents. Thus, immune stimulants and adjuvant approaches have been explored widely. Opportunities to develop effective cancer vaccines may benefit from seminal recent advances in understanding how immunosuppressive barricades are erected by tumors to mediate immune escape. This concept is precisely applicable to triple negative breast cancer due to their antigenicity. Checkpoint inhibitors are an attractive method for treatment of high-risk breast cancers. However, to leverage the efficacy of checkpoint inhibition, approaches are needed to enhance delivery of cancer antigens to the T cells. 3. Cryoablation: offers an efficacious and safe method to enhance tumor antigen presentation to the immune cells while destroying the primary tumor. This ablation method is superior by virtue of antigen preservation in situ despite toxicity to the tumor cell. Impact of cryoablation in enhancing immunological responses in tumor microenvironment are well established; however, cryoablation can also cause tumor antigen tolerance via non-specific stimulation of T cells. 4. Rationale for combining cryoablation and checkpoint inhibitors: Since checkpoint inhibitors curtail the tolerance developed by tumor antigens, and cryoablation enhances antigen presentation and T cell recruitment, it is intuitive that combination of these two approaches presents an ideal opportunity to leverage the benefits of both approaches while curtailing the limitations of either. Therefore, the investigators hypothesize in this study that their combination will improve the response rate and the degree of response.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Females
Stage I/II Cancer
Age range 18 - 90 years
Diagnoses: Invasive carcinoma, ER -, PR-, HER2- (triple negative)
Disqualifiers
Additional primary cancer
Inflammatory breast cancer
History of autoimmune disease
History of chronic immunosuppression
Trial design
Single group
Treatments tested in this trial
Cryoablation
DeviceTumor ablation before neoadjuvant chemotherapy
Cryoablation combined with PD1 Inhibitor
Combination productCombination of cryoablation with PD1 inhibitor before neoadjuvant chemotherapy
Treatment groups
Trial outcomes
Primary outcomes
Rate of Complete Pathological Response
Pathological analysis of tumor after completion of local and neoadjuvant therapy
Secondary outcomes
Percent change is Tumor Infiltrating Lymphocytes Score
tissue specimens that undergo routine pathology reporting will be evaluated for TIL score at baseline and at lumpectomy after systemic therapy. TIL score will be reported according to guidelines put forth by the International TILs Working Group. The investigators hypothesize that percent TIL score will increase by 30% from baseline.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: